<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03812939</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-1788</org_study_id>
    <nct_id>NCT03812939</nct_id>
  </id_info>
  <brief_title>Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs</brief_title>
  <official_title>An Observational Study Investigating Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of Long-acting Somastostatin analogs as treatment for type
      I gastric neuroendocrine tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in clinical symptoms</measure>
    <time_frame>6 months to 1 year</time_frame>
    <description>Measured by a questionnaire, including whether the patient presents with dyspepsia, abdominal pain, cramps, bloating, nausea, vomiting, lack of appetite, facial flushing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum Gastrin</measure>
    <time_frame>6 months to 1 year</time_frame>
    <description>Concentration of serum Gastrin after 12 hours of fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enterochromaffin-like cell (ECL) status</measure>
    <time_frame>6 months to 1 year</time_frame>
    <description>Normal Hyperplasia: ECL cell proliferation with a diameter &lt;150 μm, distinguished in: normal pattern/simple hyperplasia, linear, micronodular and adenomatoid hyperplasia.
Dysplasia: ECL cell proliferation &gt;150 but &lt;500 μm. Type I gastric carcinoid: ECL proliferation &gt;500 μm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of side-effects of Octreotide</measure>
    <time_frame>6 months to 1 year</time_frame>
    <description>Measured by a questionnaire for patients and clinician's report. Including: hypersensitivity, endocrine disorders (abnormal thyroid functions), metabolism and nutrition disorders (abnormal blood glucose), headache, bradycardia or tachycardia, dyspnea, gastrointestinal disorders (diarrhea, abdominal pain, nausea, constipation, flatulence), hepatobiliary disorders, skin disorders, injection site reaction.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric NET</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Patients will receive 6-12 monthly injections every 28 (+/- 3) days.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type I gastric NET patients from tertiary medical center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis of gastric neuroendocrine tumor.

          -  Clinical diagnosis of Type I gastric NET: neuroendocrine tumor arising from atrophic
             body gastritis (ABG diagnosis should be based on hypergastrinemia and histological
             confirmation of gastric body atrophy on multiple biopsies performed in gastric antrum
             and body).

          -  Previous esophagogastroduodenoscopy: all visible NETs resected with R0 margin,
             confirmed no visible gastric NETs left, multiple biopsies taken to evaluate gastric
             atrophy and ECL status.

          -  No tumor metastases confirmed by endoscopic ultrasonography, CT scan or somatostatin
             receptor scintigraphy.

          -  SSA therapy is recommended by physician for disease management, and has not yet begun.

          -  Written informed consent obtained prior to treatment to be consistent with local
             regulatory requirements.

        Exclusion Criteria:

          -  Pathological grading as G3 NET (Ki-67&gt;20%).

          -  Patients with a known hypersensitivity to somatostatin analogs.

          -  Known gallbladder or bile duct disease, acute or chronic pancreatitis.

          -  Known medical condition related with prolonged QT interval.

          -  Pregnant or lactating women.

          -  Patients with serious complicated infections, or nonmalignant medical illnesses that
             are uncontrolled or whose control may be jeopardized by the complications of this
             therapy.

          -  Patients with any concurrent active malignancy other than non-melanoma skin cancers or
             carcinoma-in-situ of the cervix. Patients with previous malignancies but without
             evidence of disease for &gt; 5 years will be allowed to enter the trial.

          -  Patients with a history of non-compliance to medical regimens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chuyan Chen, MD</last_name>
    <phone>+86-17701095670</phone>
    <email>chuyanchen921@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingnan Li, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103(2):119-24. doi: 10.1159/000443168. Epub 2016 Jan 19.</citation>
    <PMID>26784901</PMID>
  </reference>
  <reference>
    <citation>Merola E, Sbrozzi-Vanni A, Panzuto F, D'Ambra G, Di Giulio E, Pilozzi E, Capurso G, Lahner E, Bordi C, Annibale B, Delle Fave G. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012;95(3):207-13. doi: 10.1159/000329043. Epub 2011 Jul 30.</citation>
    <PMID>21811050</PMID>
  </reference>
  <reference>
    <citation>Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, Grimelius L, Havu N. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988;41(4):185-200. Review.</citation>
    <PMID>3072229</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 13, 2019</study_first_submitted>
  <study_first_submitted_qc>January 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>January 20, 2019</last_update_submitted>
  <last_update_submitted_qc>January 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Jing-Nan Li</investigator_full_name>
    <investigator_title>Head of Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

